Gelonghui, January 29丨Shu Taishen (300204.SZ) announced that it is expected to have a net loss of 420.6026 million yuan to 344.1294 million yuan in 2023, after deducting non-net loss of 429.0679 million yuan to 35,10555 million yuan, and operating income of 32,779.43 million yuan to 40,06.375 million yuan.

During the reporting period, the company's production and operation activities were normal. The company actively carried out various marketing and market exploration work, and focused on expanding the layout of new products. Affected by factors such as the external environment and industry policies, the company's main business revenue declined during the reporting period; the company continued to advance clinical trials based on the overall layout of future R&D projects and the company's development strategy; during the reporting period, the company's R&D investment remained at a high level due to the continuous promotion of research projects.